Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia

Haematologica. 2024 Aug 1;109(8):2732-2737. doi: 10.3324/haematol.2024.285275.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anemia, Aplastic* / chemically induced
  • Anemia, Aplastic* / drug therapy
  • Antimetabolites, Antineoplastic / adverse effects
  • Antimetabolites, Antineoplastic / therapeutic use
  • Azacitidine / adverse effects
  • Azacitidine / therapeutic use
  • DNA Methylation / drug effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / drug therapy
  • Neoplasms, Second Primary / etiology

Substances

  • Antimetabolites, Antineoplastic
  • Azacitidine